P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia

Stefania Trino, Luciana De Luca, Ilaria Laurenzana, Antonella Caivano, Luigi Del Vecchio, Giovanni Martinelli, Pellegrino Musto

Research output: Contribution to journalArticle

Abstract

The tumor suppressor p53 is a canonical regulator of different biological functions, like apoptosis, cell cycle arrest, DNA repair, and genomic stability. This gene is frequently altered in human tumors generally by point mutations or deletions. Conversely, in acute lymphoblastic leukemia (ALL) genomic alterations of TP53 are rather uncommon, and prevalently occur in patients at relapse or with poor prognosis. On the other hand, p53 pathway is often compromised by the inactivation of its regulatory proteins, as MDM2 and ARF. MDM2 inhibitor molecules are able to antagonize p53-MDM2 interaction allowing p53 to exert tumor suppressor transcriptional regulation and to induce apoptotic pathways. Recent preclinical and clinical studies propose that MDM2 targeted therapy represents a promising anticancer strategy restoring p53 dependent mechanisms in ALL disease. Here, we discussed the use of new small molecule targeting p53 pathways as a promising drug target therapy in ALL.

Original languageEnglish
Pages (from-to)491
JournalFrontiers in Pharmacology
Volume7
DOIs
Publication statusPublished - 2016

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms
Genomic Instability
Cell Cycle Checkpoints
Point Mutation
DNA Repair
Therapeutics
Apoptosis
Recurrence
Drug Therapy
Genes
Proteins

Keywords

  • Review
  • Journal Article

Cite this

P53-MDM2 Pathway : Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. / Trino, Stefania; De Luca, Luciana; Laurenzana, Ilaria; Caivano, Antonella; Del Vecchio, Luigi; Martinelli, Giovanni; Musto, Pellegrino.

In: Frontiers in Pharmacology, Vol. 7, 2016, p. 491.

Research output: Contribution to journalArticle

@article{a1de009cf7b54024ac791de2db54379e,
title = "P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia",
abstract = "The tumor suppressor p53 is a canonical regulator of different biological functions, like apoptosis, cell cycle arrest, DNA repair, and genomic stability. This gene is frequently altered in human tumors generally by point mutations or deletions. Conversely, in acute lymphoblastic leukemia (ALL) genomic alterations of TP53 are rather uncommon, and prevalently occur in patients at relapse or with poor prognosis. On the other hand, p53 pathway is often compromised by the inactivation of its regulatory proteins, as MDM2 and ARF. MDM2 inhibitor molecules are able to antagonize p53-MDM2 interaction allowing p53 to exert tumor suppressor transcriptional regulation and to induce apoptotic pathways. Recent preclinical and clinical studies propose that MDM2 targeted therapy represents a promising anticancer strategy restoring p53 dependent mechanisms in ALL disease. Here, we discussed the use of new small molecule targeting p53 pathways as a promising drug target therapy in ALL.",
keywords = "Review, Journal Article",
author = "Stefania Trino and {De Luca}, Luciana and Ilaria Laurenzana and Antonella Caivano and {Del Vecchio}, Luigi and Giovanni Martinelli and Pellegrino Musto",
year = "2016",
doi = "10.3389/fphar.2016.00491",
language = "English",
volume = "7",
pages = "491",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - P53-MDM2 Pathway

T2 - Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia

AU - Trino, Stefania

AU - De Luca, Luciana

AU - Laurenzana, Ilaria

AU - Caivano, Antonella

AU - Del Vecchio, Luigi

AU - Martinelli, Giovanni

AU - Musto, Pellegrino

PY - 2016

Y1 - 2016

N2 - The tumor suppressor p53 is a canonical regulator of different biological functions, like apoptosis, cell cycle arrest, DNA repair, and genomic stability. This gene is frequently altered in human tumors generally by point mutations or deletions. Conversely, in acute lymphoblastic leukemia (ALL) genomic alterations of TP53 are rather uncommon, and prevalently occur in patients at relapse or with poor prognosis. On the other hand, p53 pathway is often compromised by the inactivation of its regulatory proteins, as MDM2 and ARF. MDM2 inhibitor molecules are able to antagonize p53-MDM2 interaction allowing p53 to exert tumor suppressor transcriptional regulation and to induce apoptotic pathways. Recent preclinical and clinical studies propose that MDM2 targeted therapy represents a promising anticancer strategy restoring p53 dependent mechanisms in ALL disease. Here, we discussed the use of new small molecule targeting p53 pathways as a promising drug target therapy in ALL.

AB - The tumor suppressor p53 is a canonical regulator of different biological functions, like apoptosis, cell cycle arrest, DNA repair, and genomic stability. This gene is frequently altered in human tumors generally by point mutations or deletions. Conversely, in acute lymphoblastic leukemia (ALL) genomic alterations of TP53 are rather uncommon, and prevalently occur in patients at relapse or with poor prognosis. On the other hand, p53 pathway is often compromised by the inactivation of its regulatory proteins, as MDM2 and ARF. MDM2 inhibitor molecules are able to antagonize p53-MDM2 interaction allowing p53 to exert tumor suppressor transcriptional regulation and to induce apoptotic pathways. Recent preclinical and clinical studies propose that MDM2 targeted therapy represents a promising anticancer strategy restoring p53 dependent mechanisms in ALL disease. Here, we discussed the use of new small molecule targeting p53 pathways as a promising drug target therapy in ALL.

KW - Review

KW - Journal Article

U2 - 10.3389/fphar.2016.00491

DO - 10.3389/fphar.2016.00491

M3 - Article

C2 - 28018226

VL - 7

SP - 491

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

ER -